GlassScriptPhysician profile
Jonathan E Holloway
NPI 1760089841
$3,223.79
in general payments reported to CMS, 2019-2025
32 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $524 · 2024: $1,005 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,930 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,929.84 |
| Education | $293.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $763.59 | 2023-2025 | Enhertu, Imfinzi, Datroway |
| Pfizer INC. | $286.18 | 2023-2025 | |
| Seagen INC. | $248.15 | 2023-2025 | Adcetris, Tukysa |
| Novartis Pharmaceuticals Corporation | $198.25 | 2024-2025 | |
| Incyte Corporation | $181.11 | 2025 | Jakafi, Monjuvi, Zynyz |
| Lilly USA, LLC | $174.04 | 2023-2025 | Verzenio, Jaypirca |
| Merck Sharp & Dohme LLC | $153.22 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.77 | 2025 | |
| Janssen Biotech, INC. | $142.64 | 2023-2025 | Darzalex, Erleada, Imbruvica |
| Genzyme Corporation | $110.87 | 2023-2024 | |
| Beigene USA, INC. | $82.21 | 2024 | Brukinsa |
| Abbvie INC. | $81.25 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.24 | 2023-2024 | Ninlaro, Iclusig |
| Eisai INC. | $58.72 | 2025 | |
| Teleflex LLC | $54.97 | 2024 | Arrow |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $49.29 | 2024 | |
| Celgene Corporation | $48.82 | 2023-2024 | Reblozyl |
| Daiichi Sankyo INC. | $48.80 | 2025 | Vanflyta |
| Aveo Pharmaceuticals, INC. | $45.64 | 2025 | |
| Jazz Pharmaceuticals INC. | $37.11 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.09 | 2024 | Opdualag |
| Genentech USA, INC. | $36.30 | 2024-2025 | Alecensa, Tecentriq, Venclexta |
| Coherus Oncology, INC. | $30.84 | 2025 | Loqtorzi |
| Fennec Pharmaceuticals, INC. | $21.08 | 2024 | Pedmark |
| Pharmacyclics LLC, An Abbvie Company | $20.09 | 2023 | Imbruvica |
| Puma Biotechnology, INC. | $19.15 | 2023 | |
| Amneal Pharmaceuticals LLC | $18.64 | 2024 | Neupogen, Avastin, Neulasta |
| Sumitomo Pharma America, INC. | $15.53 | 2024 | Orgovyx |
| Kite Pharma, INC. | $15.02 | 2025 | Yescarta |
| Astellas Pharma US INC | $15.01 | 2025 | Vyloy |
| Tempus Ai, INC | $14.11 | 2024 | |
| Glaxosmithkline, LLC. | $14.06 | 2024 | Ojjaara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Holloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.